Literature DB >> 7832279

Structural integrity and identification of causes of liver allograft dysfunction occurring more than 5 years after transplantation.

O Pappo1, H Ramos, T E Starzl, J J Fung, A J Demetris.   

Abstract

The clinicopathologic features of liver allograft dysfunction occurring in 51 symptomatic recipients after more than 5 years' survival (mean 7.1 years) with the same hepatic allograft were compared with those of a similar group of 14 asymptomatic patients (mean survival, 9.9 years) who underwent a nonclinically indicated protocol liver biopsy evaluation. Predictably, patients who had clinically indicated biopsies more frequently showed histopathologic alterations (76% versus 36%, p < 0.002). After detailed clinicopathologic correlation, the changes in the symptomatic patients were attributed primarily to definite or presumed viral hepatitis in 17 of 51 (33%) patients, 11 of whom had recurrent viral disease; seven of 51 (14%) had nonviral recurrent original disease, three (6%) had obstructive cholangiopathy, and 11 (22%) had acute and/or chronic rejection. In 13 of 51 (25%) of the symptomatic patients, the clinical and pathologic abnormalities were minimal. Long-term liver allograft survival in nine of 14 (64%) of the asymptomatic patients was associated with minimally abnormal histologic alterations. Two of the asymptomatic patients had obstructive cholangiopathy; two others has recurrence of the original disease and one has possible viral hepatitis. Viral hepatitis types B and C, alcoholic liver disease, autoimmune hepatitis, granulomatous hepatitis (not otherwise specified), and probably primary biliary cirrhosis and primary sclerosing cholangitis were shown to recur after hepatic transplantation. The histopathologic changes associated with acute and chronic rejection frequently overlapped with other syndromes causing late dysfunction, such as chronic viral or autoimmune hepatitis, primary biliary cirrhosis, or primary sclerosing cholangitis; more than one insult could be identified in 15 cases, which made the differential diagnosis of causes of late liver allograft dysfunction much more difficult than early after hepatic transplantation. It is important to correlate the biopsy findings with the liver injury tests, the results of viral and autoimmune antibody serologic studies, and review of previous biopsies and to be aware of the original disease, recent changes in immunosuppression, and results of therapeutic intervention(s) to identify correctly the causes of liver allograft dysfunction in this patient population.

Entities:  

Mesh:

Year:  1995        PMID: 7832279      PMCID: PMC3095883          DOI: 10.1097/00000478-199502000-00008

Source DB:  PubMed          Journal:  Am J Surg Pathol        ISSN: 0147-5185            Impact factor:   6.394


  40 in total

1.  Liver biopsy in the long-term follow-up of liver transplant patients: still the gold standard.

Authors:  C A Riely; S R Vera
Journal:  Gastroenterology       Date:  1990-10       Impact factor: 22.682

2.  Disease recurrence following liver transplantation.

Authors:  J Hart; R W Busuttil; K J Lewin
Journal:  Am J Surg Pathol       Date:  1990       Impact factor: 6.394

3.  The pathology of liver allografts surviving longer than one year.

Authors:  R E Nakhleh; S J Schwarzenberg; J Bloomer; W Payne; D C Snover
Journal:  Hepatology       Date:  1990-03       Impact factor: 17.425

Review 4.  Some recent advances in cardiac pathology.

Authors:  M E Billingham
Journal:  Hum Pathol       Date:  1979-07       Impact factor: 3.466

5.  Evolution of hepatitis B virus liver disease after hepatic replacement. Practical and theoretical considerations.

Authors:  A J Demetris; S Todo; D H Van Thiel; J J Fung; Y Iwaki; G Sysyn; W Ming; J Trager; T E Starzl
Journal:  Am J Pathol       Date:  1990-09       Impact factor: 4.307

6.  Azathioprine induced liver disease: nodular regenerative hyperplasia of the liver and perivenous fibrosis in a patient treated for multiple sclerosis.

Authors:  F Mion; B Napoleon; F Berger; M Chevallier; S Bonvoisin; L Descos
Journal:  Gut       Date:  1991-06       Impact factor: 23.059

7.  Chronic rejection after liver transplantation: a study of clinical, histopathological and immunological features.

Authors:  D K Freese; D C Snover; H L Sharp; C R Gross; S K Savick; W D Payne
Journal:  Hepatology       Date:  1991-05       Impact factor: 17.425

8.  Conversion of liver allograft recipients from cyclosporine to FK506 immunosuppressive therapy--a clinicopathologic study of 96 patients.

Authors:  A J Demetris; J J Fung; S Todo; J McCauley; A Jain; S Takaya; M Alessiani; K Abu-Elmagd; D H Van Thiel; T E Starzl
Journal:  Transplantation       Date:  1992-05       Impact factor: 4.939

9.  Steroid withdrawal from long-term immunosuppression in liver allograft recipients.

Authors:  R T Padbury; B K Gunson; B Dousset; S G Hubscher; J A Buckels; J M Neuberger; E Elias; P McMaster
Journal:  Transplantation       Date:  1993-04       Impact factor: 4.939

10.  Nodular regenerative hyperplasia of the liver in hematologic disorders: a possible response to obliterative portal venopathy. A morphometric study of nine cases with an hypothesis on the pathogenesis.

Authors:  I R Wanless; T A Godwin; F Allen; A Feder
Journal:  Medicine (Baltimore)       Date:  1980-09       Impact factor: 1.889

View more
  15 in total

Review 1.  Chronic rejection. A general overview of histopathology and pathophysiology with emphasis on liver, heart and intestinal allografts.

Authors:  A J Demetris; N Murase; R G Lee; P Randhawa; A Zeevi; S Pham; R Duquesnoy; J J Fung; T E Starzl
Journal:  Ann Transplant       Date:  1997       Impact factor: 1.530

2.  Risks and benefits of weaning immunosuppression in liver transplant recipients: long-term follow-up.

Authors:  G V Mazariegos; J Reyes; I Marino; B Flynn; J J Fung; T E Starzl
Journal:  Transplant Proc       Date:  1997 Feb-Mar       Impact factor: 1.066

Review 3.  De novo autoimmune hepatitis in liver transplant: State-of-the-art review.

Authors:  Ranka Vukotic; Giovanni Vitale; Antonia D'Errico-Grigioni; Luigi Muratori; Pietro Andreone
Journal:  World J Gastroenterol       Date:  2016-03-14       Impact factor: 5.742

4.  Hepatic retransplantation in cholestatic liver disease: impact of the interval to retransplantation on survival and resource utilization.

Authors:  W R Kim; R H Wiesner; J J Poterucha; T M Therneau; M Malinchoc; J T Benson; J S Crippin; G B Klintmalm; J Rakela; T E Starzl; R A Krom; R W Evans; E R Dickson
Journal:  Hepatology       Date:  1999-08       Impact factor: 17.425

5.  Liver transplantation for alcoholic cirrhosis: long term follow-up and impact of disease recurrence.

Authors:  C O Bellamy; A M DiMartini; K Ruppert; A Jain; F Dodson; M Torbenson; T E Starzl; J J Fung; A J Demetris
Journal:  Transplantation       Date:  2001-08-27       Impact factor: 4.939

6.  Weaning of immunosuppression in liver transplant recipients.

Authors:  G V Mazariegos; J Reyes; I R Marino; A J Demetris; B Flynn; W Irish; J McMichael; J J Fung; T E Starzl
Journal:  Transplantation       Date:  1997-01-27       Impact factor: 4.939

7.  Protocol liver biopsies in long-term management of patients transplanted for hepatitis B-related liver disease.

Authors:  Stefano Targhetta; Federico Villamil; Paolo Inturri; Patrizia Pontisso; Stefano Fagiuoli; Umberto Cillo; Attilio Cecchetto; Simona Gianni; Remo Naccarato; Patrizia Burra
Journal:  World J Gastroenterol       Date:  2006-03-21       Impact factor: 5.742

Review 8.  Pediatric liver transplantation.

Authors:  Marco Spada; Silvia Riva; Giuseppe Maggiore; Davide Cintorino; Bruno Gridelli
Journal:  World J Gastroenterol       Date:  2009-02-14       Impact factor: 5.742

9.  Weaning of immunosuppression in long-term liver transplant recipients.

Authors:  H C Ramos; J Reyes; K Abu-Elmagd; A Zeevi; N Reinsmoen; A Tzakis; A J Demetris; J J Fung; B Flynn; J McMichael
Journal:  Transplantation       Date:  1995-01-27       Impact factor: 4.939

Review 10.  Diagnosis, pathogenesis, and treatment of autoimmune hepatitis after liver transplantation.

Authors:  Albert J Czaja
Journal:  Dig Dis Sci       Date:  2012-05-06       Impact factor: 3.199

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.